Identité

Omarigliptin Impurity 28

Non indiqué · C20H26F2N2O4

01Identité

Lazychem IDLC-36161
CAS RNNon indiqué
PubChem CID118613910
Molecular formulaC20H26F2N2O4
Molecular weight396.4 g/mol
IUPAC nametert-butyl N-[(2R,3S)-2-(2,5-difluorophenyl)-5-morpholin-4-yl-3,4-dihydro-2H-pyran-3-yl]carbamate
InChIKeyGNRDFJBGJNBAGP-ZWKOTPCHSA-N

02Structure et stéréochimie

Two-dimensional chemical structure of Omarigliptin Impurity 28
Two-dimensional structure for the PubChem identity linked to this record. Confirm the identifiers before analytical use.

The parsed structure contains 3 rings, includes aromatic atoms, includes aliphatic carbon, has 2 defined stereocentres, contains at least one halogen atom. These statements are calculated from the published structure string.

Defined stereocentres2
Ring count3
Secondary amines0
Tertiary amines1
SMILESCC(C)(C)OC(=O)N[C@H]1CC(=CO[C@@H]1C2=C(C=CC(=C2)F)F)N3CCOCC3
InChINon indiqué

03Stereochemistry

The published structure contains 2 defined and 0 unassigned tetrahedral stereocentres. The exact wedge and dash depiction is shown above.

Defined centres2Structure assigned
Unassigned centres0Structure unspecified
Assignment statusFully assignedExact published identity
Tetrahedral upper bound≤ 4Before symmetry reduction

Published same-connectivity configurations

1 record

These records have the same connectivity, molecular formula and protonation layer, but a different complete InChIKey stereochemical layer. Only separately structure-linked records are shown.

No additional structure-linked configuration with the same connectivity is currently present in the LazyChem dataset.

Scope: The mathematical 2^n value is only an upper bound. Symmetry and other stereogenic elements can change the number of distinct stereoisomers. A hypothetical configuration is not published as a compound record without a verified structure identity.

04Statut en Inde

Exact-compound status is evaluated only against the published name and CAS number. Confirm the current official instrument before a regulatory decision.

05Noms et relations

API et médicament parent

Non indiqué

Noms et relations

    06Sources